摘要
目的探讨希罗达联合多西他赛治疗晚期胃癌临床疗效的观察。方法选取2010年8月~2013年8月我院接诊的84例晚期胃癌患者作为本次研究对象。按照随机数字表法分为观察组和对照组,各42例,观察组采用希罗达联合多西他赛进行治疗,对照组采用奥沙利铂联合多西他赛进行治疗,观察两组患者治疗后不良反应情况、治疗疗效。结果治疗后,观察组患者不良反应总发生率为4.76%（2/42）,低于对照组的45.23%（19/42）,差异有统计学意义（P〈0.01）;观察组治疗总有效率为80.95%（34/42）,优于对照组的52.38%（22/42）,差异有统计学意义（P〈0.01）;结论希罗达联合多西他塞治疗晚期胃癌患者临床疗效显著,能够减少患者的不良反应,延缓患者的生命,提高治疗疗效,安全有效,值得推广。
Objective To explore the clinical curative effect of xeloda combined with docetaxel in the treatment of advanced gastric cancer.Methods 84 cases of patients with advanced gastric cancer from August 2010 to August 2013 in our hospital were researched and divided randomly into observation and control groups.42 cases in each group,The observation group were treated with xeloda combined with docetaxel,The control group were treated with oxaliplatin combined with docetaxel,Observation of two groups of patients with adverse reactions after treatment,curative effect.Results After treatment,Incidence rate of adverse reactions in the observation group4.76%（2/42）less than that of control group45.23%（19/42）,the difference was statistically significant（P 〈0.01）;Total effective rate of observation group80.95%（34/42）better than that of control group 52.38%（22/42）,the difference was statistically significant（P 〈0.01）.Conclusion Xeloda in combination with docetaxel has significant clinical curative effect in the treatment of patients with advanced gastric cancer, can reduce the number of patients with adverse reactions,patients with delayed life,improve curative effect,safe and effective,it is worth promoting.
出处
《中国当代医药》
2016年第23期61-63,共3页
China Modern Medicine
基金
江西省景德镇市科技局科学技术鉴定成果(景科学鉴字2014第64号)
关键词
希罗达
多西他赛
晚期胃癌
临床疗效
Xeloda
Docetaxel
Advanced gastric cancer
Clinical curative effect
